Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Average (2021 - 2025)

Kiniksa Pharmaceuticals International's Equity Average history spans 5 years, with the latest figure at $551.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 25.99% year-over-year to $551.5 million; the TTM value through Dec 2025 reached $551.5 million, up 25.99%, while the annual FY2025 figure was $503.0 million, 14.68% up from the prior year.
  • Equity Average reached $551.5 million in Q4 2025 per KNSA's latest filing, up from $515.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $551.5 million in Q4 2025 to a low of $159.9 million in Q2 2022.
  • Average Equity Average over 5 years is $370.0 million, with a median of $408.4 million recorded in 2023.
  • Peak YoY movement for Equity Average: plummeted 36.87% in 2022, then soared 150.75% in 2023.
  • A 5-year view of Equity Average shows it stood at $199.5 million in 2021, then soared by 95.49% to $390.1 million in 2022, then rose by 8.18% to $422.0 million in 2023, then increased by 3.73% to $437.7 million in 2024, then rose by 25.99% to $551.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Equity Average are $551.5 million (Q4 2025), $515.2 million (Q3 2025), and $476.2 million (Q2 2025).